Could CEREBAIN BIOTECH CORPORATION NEW (OTCMKTS:CBBT) Go Up After Its Newest Short Interest Report?

January 14, 2018 - By Marie Mckinney

The stock of CEREBAIN BIOTECH CORPORATION NEW (OTCMKTS:CBBT) registered an increase of 112.5% in short interest. CBBT’s total short interest was 1,700 shares in January as published by FINRA. Its up 112.5% from 800 shares, reported previously.

The stock increased 53.85% or $0.07 during the last trading session, reaching $0.2. About 19,900 shares traded. Cerebain Biotech Corp. (OTCMKTS:CBBT) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Cerebain Biotech Corp., a biomedical company, focuses on the discovery of products for the treatment of AlzheimerÂ’s disease. The company has market cap of $1.66 million. The Company’s products would include medical device solutions, as well as synthetic drug solutions. It currently has negative earnings. The firm was formerly known as Discount Dental Materials, Inc. and changed its name to Cerebain Biotech Corp. in June 2014.

More important recent Cerebain Biotech Corp. (OTCMKTS:CBBT) news were published by: Businesswire.com which released: “Governor Scott McCallum, Representing Cerebain Biotech, to Present at US …” on June 01, 2016, also Businesswire.com published article titled: “Cerebain Biotech Receives Financial Commitment of Two Million Dollars”, Businesswire.com published: “Cerebain Biotech Announces Business Relocation into the Heart of Orange County …” on May 04, 2016. More interesting news about Cerebain Biotech Corp. (OTCMKTS:CBBT) was released by: Businesswire.com and their article: “Cerebain Biotech Engages NMS Capital Advisors” with publication date: March 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.